# Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

> **NCT00193349** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 60 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Irinotecan
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00193349
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 60 (—)
- **Last updated:** 2010-06-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193349, "Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00193349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*